Michael Potnek
Primary Care · Milwaukee, WINPI 1760966170
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 98.2% of it on its own, with 11 other manufacturers making up the rest. Among primary care clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $308.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$69K
- Boehringer Ingelheim$825
- AbbVie$244
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29
- Alkermes, Inc.$29
- Mylan Specialty L.p.$27
- plus $88 from 6 others
What the payments were for
- Consulting fees$8,98513%
- Speaking & faculty fees$40,78058%
- Travel & lodging$15,36422%
- Food & beverage$5,5088%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 206 | $69,395 |
| Boehringer Ingelheim | 1 | $825 |
| AbbVie | 13 | $244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Alkermes, Inc. | 1 | $29 |
| Mylan Specialty L.p. | 1 | $27 |
| Pfizer | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Merck | 1 | $11 |
| Organon | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$59,258
- STIOLTO RESPIMAT$825
How this compares
$70,636 in reported general payments places this provider in the 95th percentile of 52 primary care providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 23 | $14,304 |
| EliquisApixaban | 13 | $12,429 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,921 |
| Atorvastatin Calcium | 129 | $1,137 |
| Aripiprazole | 14 | $689 |
| Gabapentin | 41 | $650 |
| Chlorthalidone | 33 | $475 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $431 |
| Amlodipine Besylate | 61 | $364 |
| Omeprazole | 20 | $287 |
| Metformin Hcl | 31 | $253 |
| Pantoprazole Sodium | 30 | $249 |
| Venlafaxine Hcl | 22 | $233 |
| Allopurinol | 21 | $229 |
| Meloxicam | 18 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $244 | $14,30423 claims |
| PfizerEliquis | $21 | $12,42913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 primary care providers in Wisconsin.
Other primary care in Milwaukee
- Kelly StoneMilwaukee$2K
- Courtney LammMilwaukee$2K
- Mary WiseMilwaukee$2K
- Alexandra KochMilwaukee$525
- Jana ZullnerMilwaukee$461
- Lisa KorbanMilwaukee$301
- Heejin KwonMilwaukee$267
- Lauren NewellMilwaukee$243
- Cheryl GatesMilwaukee$120
- Blanca BobadillaMilwaukee$107
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.